Tuberculosis is the leading infectious cause of death worldwide, with 9·6 million cases and 1·5 million deaths reported in 2014. WHO estimates 480 000 cases of these were multidrug resistant (MDR). Less than half of patients who entered into treatment for MDR tuberculosis successfully completed that treatment, mainly due to high mortality and loss to follow-up. These in turn illustrate weaknesses in current treatment regimens and national tuberculosis programmes, coupled with operational treatment challenges. In this Review we provide an update on recent developments in the tuberculosis drug-development pipeline (including new and repurposed antimicrobials and host-directed drugs) as they are applied to new regimens to shorten and improve outcomes of tuberculosis treatment. Several new or repurposed antimicrobial drugs are in advanced trial stages for MDR tuberculosis, and two new antimicrobial drug candidates are in early-stage trials. Several trials to reduce the duration of therapy in MDR and drug-susceptible tuberculosis are ongoing. A wide range of candidate host-directed therapies are being developed to accelerate eradication of infection, prevent new drug resistance, and prevent permanent lung injury. As these drugs have been approved for other clinical indications, they are now ready for repurposing for tuberculosis in phase 2 clinical trials. We assess risks associated with evaluation of new treatment regimens, and highlight opportunities to advance tuberculosis research generally through regulatory innovation in MDR tuberculosis. Progress in tuberculosis-specifi c biomarkers (including culture conversion, PET and CT imaging, and gene expression profi les) can support this innovation. Several global initiatives now provide unique opportunities to tackle the tuberculosis epidemic through collaborative partnerships between high-income countries and middle-income and low-income countries for clinical trials training and research, allowing funders to coordinate several national and regional programmes for greatest overall eff ect.
Introduction
WHO estimated that in 2014, 9·6 million people (5·4 million men, 3·2 million women, and 1 million children) fell ill with tuberculosis worldwide. 1 The resulting 1·5 million deaths made tuberculosis the leading infectious cause of death globally. 1 WHO further estimated 480 000 cases (and 190 000 deaths) were multidrug resistant (MDR; defi ned as resistant at a minimum to rifampicin and isoniazid; fi gure 1), and only a quarter of these cases were reported. An estimated 9·7% of cases of MDR tuberculosis were extensively drug resistant (XDR; defi ned as MDR plus additional resistance to at least one fl uoroquinolone and one second-line injectable drug), and have been reported in 105 countries. 1 In 2014, MDR tuberculosis accounted for 3·3% of new tuberculosis cases and 20% of previously treated cases. 1 Only half of these patients will successfully complete treatment. Of those patients with outcome data, death (16%), loss to follow-up (16%), and treatment failure (10%) are common 1 due to weaknesses in current regimens, national programmes, and operational challenges. MDR tuberculosis thus constitutes a major threat to global public health security. WHO's 2015 annual tuberculosis report 1 states that "without new tuberculosis drugs and regimens, it will be very diffi cult to improve treatment outcomes in the near future", adding "intensifi ed research and development is one of the three pillars of WHO's Post-2015 Global Tuberculosis Strategy, and will play a crucial role in accelerating the reductions in tuberculosis incidence and mortality required to reach global tuberculosis targets by 2035".
Many unmet medical needs exist for all forms of tuberculosis (panel) . In this Review we describe how these needs can be addressed by recent developments in new and repurposed antimicrobial drugs and hostdirected therapies, advances in biomarkers, strategies for regimen development, and opportunities aff orded by regulatory innovation.
New and repurposed antimicrobial drugs
Regimens comprising entirely new drugs would be an important therapeutic advance, because they would reduce the present requirement for drug-susceptibility testing, thus simplifying patient care. The current tuberculosis antimicrobial drug pipeline shows eight drugs in phase 2-3 trials (fi gure 2). Two new drugs (bedaquiline and delamanid) are in confi rmatory phase 3 trials, having received accelerated approvals for MDR tuberculosis based on phase 2 data in 2012, and 2014, respectively. However, of the six remaining drugs, only two (sutezolid [an oxazolidinone] and pretomanid [PA-824; a nitroimidazole]) are new compounds. No trials of sutezolid are being done and hepatic safety concerns emerged during the largest trial of pretomanid. Ongoing studies of rifamycins (rifapentine [a long-acting but highly protein-bound rifamycin] and rifampicin) and fl uoroquinolones (levofl oxacin and moxifl oxacin) seek mainly to optimise or defi ne their roles in drug-susceptible tuberculosis. Only two new compounds have entered phase 1 trials: Q203, a novel ATP synthetase inhibitor (ClinicalTrials.gov NCT02530710), and TBA-354, a nitroimidazole (NCT02606214). However, as of January, 2016, the only study of TBA-354 had suspended recruitment. So far, studies of SQ109-an asymmetrical diamine-have not shown antituberculosis activity in sputum, alone or in combination with rifampicin over 14 days, 2 or in either of two rifampicin-containing regimens over 3 months 3 (table 1) . Additional studies of SQ109 to establish its maximum tolerated dose and to examine pharmacokinetic drug-drug interactions with rifampicin more closely will be needed if SQ109 is to advance further. Thus, the near-term availability of additional drugs representing new antimicrobial drug classes to be combined with bedaquiline and delamanid in entirely new regimens will not be suffi cient. As a result, existing antimicrobial drug classes have to be relied on or consider host-directed therapies for development of new tuberculosis regimens.
Oxazolidinones act by binding to 23S RNA, blocking translation and thereby protein synthesis. Their clinical success depends on diff erential eff ects on bacteria versus mitochondria. Mitochondrial eff ects manifest over time as haematological, neurological, and ophthalmological toxicities. A landmark study 14 of linezolid added to an unsuccessful regimen in 39 patients with XDR tuberculosis reported that sputum-culture conversion on solid culture medium occurred in 35% after 2 months, and 87% after 6 months, thus showing the remarkably low frequency of spontaneous oxazolidinone resistance in vitro. However, this study 14 also reported that 82% of patients experienced linezolid toxicity, which led to three permanent discontinuations of treatment. As a result, studies of
Panel: Unmet medical needs in tuberculosis
• New regimens to shorten treatment duration without increasing the risk of patient relapse. Current targets are less than 6 months for drug-sensitive tuberculosis and less than 12 months for drug-resistant disease. Shorter regimens will improve patient adherence, reduce cumulative drug toxicities, and reduce clinics' workloads.
• Better-tolerated treatments than those available and that can eff ectively eradicate drug-resistant Mycobacterium tuberculosis infection while preventing new resistance and treatment failure. Drugs used for multidrug-resistant (MDR) tuberculosis are poorly tolerated, resulting in reduced patient adherence and increased risk of unsuccessful treatment.
• Treatments to prevent permanent lung injury and functional impairment, which in half of patients results in chronic cough, breathlessness, impaired lung function, and reduced longevity, despite treatment success. These risks seem to be increased in patients with MDR tuberculosis.
• Improved biomarkers to guide patient care and accelerate drug development.
• Improved survival in patients with drug-resistant tuberculosis and HIV co-infection.
• Improved treatments for suspected latent M tuberculosis infection, including of drug-resistant strains. Review linezolid seek to identify doses that minimise toxic eff ects without compromising effi cacy. However, it might be challenging because effi cacy and toxicity are due to similar mechanisms (inhibition of protein synthesis) in similar targets (bacteria and mitochondria). Sutezolid is a linezolid analogue with greater antimycobacterial activity than linezolid in vitro, 15 in various intracellular and animal models [16] [17] [18] [19] and in ex-vivo whole blood cultures. 20 Sutezolid is active against non-replicating Mycobacterium tuberculosis in vitro and in vivo. 21 Studies 22 using hollow fi bre culture models showed more-than-additive eff ects for combination of this drug with rifamycins. No haematological toxic eff ects were recorded in phase 1 trials at 600 mg twice a day for 28 days, which is thought to represent reduced inhibition of mitochondrial protein synthesis. 20, 23 Sutezolid dose of 600 mg twice a day and 1200 mg once a day were well tolerated and showed sputum early bactericidal activity (EBA) in patients with tuberculosis of −0·09 log/day Review and −0·07 log/day, respectively, over 14 days. 24 AZD5847 is the only other oxazolidinone that has been clinically assessed for antimycobacterial activity. In one trial, 25 doses from 500 mg once a day up to 800 mg twice a day were studied in 75 patients over 14 days; EBA was −0·04 log/day for 500 mg twice a day dose and −0·02 log/day for those receiving 800 mg twice a day. 25 However, 17 severe or lifethreatening adverse events, including serious hepatic and haematological toxicities, occurred in patients treated with AZD5847, whereas no adverse events were reported in controls. No further studies are planned.
Rifamycins act by binding rpoB and blocking RNA synthesis. The introduction of rifampicin 40 years ago permitted treatment to be shortened from 16 months to 8 months. 26 Interest is renewed to assess higher doses than approved. Rifabutin, a rifampicin derivative approved by US Federal Drug Administration (FDA) in 1992 for prevention of disseminated Mycobacterium avium infection, is unique among licensed rifamycins in that it seems to be active against MDR tuberculosis strains with rpoB mutations at codon 516. These strains remain rifabutin susceptible (minimum inhibitory concentration twice as wild-type) despite rifampicin resistance (minimum inhibitory con centration >ten times that of wildtype). 27, 28 These pre dominate among MDR isolates in the South African Eastern Cape, and seem to represent a third of South Africa's MDR tuberculosis isolates overall, which can be detected by the B probe of the Cepheid GeneXpert TB-RIF (Cepheid, Sunnyvale, CA, USA). A Cochrane review 29 of fi ve trials in 924 patients with drug-sensitive tuberculosis compared rifabutin and rifampicin and reported no diff erences in rates of treatment success, recurrence, or adverse events. 29 Rifabutin has minimal induction of CYP3A4, permitting its use with many rifampicin-incompatible drugs due to its pharmacokinetic drug-drug interactions.
Clofazimine is a fat-soluble riminophenazine with both antimicrobial 30, 31 and anti-infl ammatory 32 properties, and is used with rifampicin and dapsone in the treatment of leprosy. A benefi t of clofazimine in MDR tuberculosis suggested by uncontrolled trials 33, 34 was supported in a randomised controlled trial 6 (table 1) . Clofazimine shows treatment-shortening activity in Balb/c mice, 35 but not in C3HeB/FeJ mice that form necrotic granulomas. 36 Concerns regarding skin discolouration (and as a result possible stigmatisation), increased QT, and pharmacokinetic drug-drug interactions will hinder its advance in use for drug-sensitive tuberculosis.
Carbapenems might have a role in MDR tuberculosis regimens, based on in-vitro activity and uncontrolled case reports. [37] [38] [39] [40] [41] Early trials of faropenem (NCT02349841) and meropenem (NCT02393586) are underway. Sulfonamides have also been proposed as antituberculosis drugs based on in-vitro susceptibility, but no prospective trials have yet been done. Several studies of cotrimoxazole prophylaxis in HIV-infected people in Africa reported no eff ect on tuberculosis incidence.
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Host-directed therapeutics to eradicate infection and prevent lung damage
Scientifi c interest has recently increased in targeting of host factors to identify new treatments for MDR tuberculosis. Host-directed therapies (HDTs)-including new and repurposed drugs, biologics, and cellular therapies-have been proposed to shorten treatment duration, prevent resistance, and reduce lung injury, by promoting autophagy, antimicrobial peptide production, other macrophage eff ector mechanisms, and inhibiting mechanisms causing lung infl ammation and matrix destruction. [45] [46] [47] Lung damage in tuberculosis is pervasive and permanent. Findings from a study 48 showed that at diagnosis, patients with tuberculosis had lost a third of their expected 1 s forced expiratory volume (FEV1), recovering only a small fraction by the end of treatment. Another study 49 reported abnormal spirometry in 48 (68%) of 71 patients up to 16 years after being cured of tuberculosis, in relation to radiographical extent of disease and amount of sputum at diagnosis. A study 50 in 27 660 South African gold miners after 5 years noted progressive FEV1 loss with each tuberculosis recurrence. Patients who have previously had tuberculosis are at an increased risk of death due to pneumonia and septicaemia, 51 and have reduced longevity 52 despite being cured of tuberculosis. Several infl ammatory mechanisms contribute to lung destruction in tuberculosis, including local production and activation of matrix metalloproteinases (MMPs) by tumour necrosis factor (TNF). 53 Although lung injury has largely not been assessed in modern tuberculosis trials, several trials completed in the 1960s assessed the pulmonary eff ects of adjunctive corticosteroids. A review 54 in 1997 concluded that corticosteroids generally hastened resolution of signs and symptoms, but yielded no long-term benefi t. Findings from a 2013 meta-analysis 55 showed corticosteroids reduced tuberculosis mortality, but its interpretations were heavily infl uenced by studies of CNS disease. A 2014 meta-regression analysis 56 reported dose-dependent acceleration of sputum-culture conversion by corticosteroids. Several mechanisms have been identifi ed that reduce antimycobacterial drug eff ects against intracellular bacilli in activated macrophages including impaired lesional drug penetration, 57 reduced mycobacterial drug uptake, 58 and enhanced drug effl ux. 59 Additionally, experiments completed in the past year suggest that the low concentrations of nitric oxide produced by macrophages in this setting substantially change bacillary replication, metabolism, and biosynthesis, inducing a state of phenotypic tolerance to currently available tuberculosis drugs (Russell D, Cornell University, personal communication). These mechanisms increase the risk of treatment failure (ie, the inability to eliminate replicating M tuberculosis from sputum due to genetic selection of drug-resistant mutants and patient relapse by reducing antituberculosis drug activity), 60 thereby broadening the possible www.thelancet.com/infection Vol 16 April 2016 e38 Review objectives for anti-infl ammatory host-directed therapies beyond that of lung protection.
The Host-Directed Therapies Consortium Network was launched in April, 2015, with 64 global partners to take forward trials of tuberculosis host-directed therapies. It concluded that several drugs approved for other diseases are ready for clinical assessment in phase 2 trials, including imatinib, metformin, doxycycline, and CC-11050 (Celgene, Summit, NJ, USA).
Imatinib is a tyrosine kinase inhibitor approved for the treat ment of chronic myelogenous leukaemia. In M tuberculosis-infected mice and macrophages, low doses of imatinib promoted myelopoiesis, phagosome maturation and acidifi cation, and autophagy, thereby reducing bacillary survival. [61] [62] [63] [64] Favourable interactions of imatinib and pyrazinamide are anticipated based on imatinib's mechanism of action (phagosome acidification). Ongoing studies at the Emory University (Atlanta, GA, USA) and the Tulane University (New Orleans, LA, USA) are examining the activity of low dose imatinib added to moxifl oxacin, pyrazinamide, and ethambutol in chronically M tuberculosis-infected macaques. Imatinib is generally very well tolerated, 65 especially at the doses anticipated anticipated for treatment of human tuberculosis. Imatinib's metabolism is greatly aff ected by rifampicin because of eff ects on CYP3A4. As an autophagy inducer, imatinib might have additional antiinfl ammatory properties. However, a potential concern regarding neutrophil-induced lung damage makes its initial study, in our opinion, most applicable in patients with MDR tuberculosis, in whom the benefi t-to-risk balance is more favourable. Generic forms of this drug became available internationally in 2015.
Metformin is a treatment of choice for diabetes. It was identifi ed as an autophagy inducer in a screen of adenosine monophosphate-activated protein kinase activators that inhibited intracellular growth of M tuberculosis. 66 Subsequent studies 66 have reported that clinically achieved doses and concentrations of metformin reduced colony-forming unit counts in M tuberculosis-infected macrophages in vitro and in acutely infected mice. To assess the potential eff ect of metformin on human tuberculosis, a study 66 assessed the records of patients with tuberculosis and diabetes of the Singapore tuberculosis control programme. Singhal and colleagues 66 showed that those receiving metformin were less likely to have cavitary disease at diagnosis and were less likely to die during the fi rst year after diagnosis.
Doxycycline non-specifi cally inhibits MMPs at subantimicrobial concentrations. MMPs cause tissue damage through the loss of collagen and other structural proteins; they have been shown in animal models of tuber culosis to play an important part in lung destruction. 67 An adjunctive role has been proposed for doxycycline on the basis of MMP inhibition in the lung. MMPs and products of collagen turnover can be readily measured in sputum, plasma, and urine.
CC-11050 is a type 4 phosphodiesterase inhibitor and was the backup compound for apremilast (a drug now approved for several anti-infl ammatory diseases). 68, 69 Similar to apremilast, CC-11050 inhibits production of several pro-infl ammatory cytokines (including TNF) by increasing cellular cyclic AMP. In mice and rabbits chronically infected with M tuberculosis, CC-11050 reduces the number and size of lung granulomas and accelerates isoniazid-induced bacillary clearance. [70] [71] [72] As a result, this drug seems to have potential to reduce tuberculosis treatment duration and might reduce permanent lung injury due to tuberculosis.
Advances in tuberculosis biomarkers
Biomarkers are measurable characteristics that can form the basis of surrogate endpoints, thereby accelerating drug development. 73 However, progress in tuberculosis biomarkers has been slow. [74] [75] [76] In 2015, a blueprint identifi ed important research steps for advances in this area and emphasised collaboration and harmonisation of eff orts. 77 Four areas of particular interest for new tuberculosis regimens are sputum-culture status, PET, whole-blood bactericidal activity, and gene expression profi les. Sputum-culture status on solid medium after 8 weeks of treatment is the most studied tuberculosis biomarker predictor for treatment failure and relapse (fi gure 3). An analysis 78 of 1712 patients with MDR tuberculosis showed culture conversion after 2 months was strongly associated with treatment success versus treatment failure or death (odds ratio 3·6, positive predictive value 80%). Findings from a 2015 study 6 of clofazimine in 105 patients with MDR tuberculosis supported this conclusion. An analysis of 7793 patients enrolled in a prospective, randomised, clinical trial 80 identifi ed 2-month culture status and duration as independent predictors of relapse in a simple statistical model. The model was independently validated with data from the eight arms of the REMox, 7 RIFAQUIN, 8 and OFLOTUB 9 trials, showing that noted and predicted relapse rates were highly correlated (R² 0·86). 79 A simplifi ed, updated version of the model using the combined dataset of 11 181 patients can be accessed via an online calculator. 81 The model predicts that if a new 4-month regimen reduces the proportion of patients positive on solid culture at month 2 to 1%, it would reduce to a 10% risk of a relapse to more than 10% in a phase 3 trial with 680 participants per group. About 15% are positive at month 2 during standard therapy. The 1% target for a 4-month regimen is far lower than anticipated. Culture status after 8 weeks of treatment is the sole tuberculosis biomarker meeting the regulatory criteria proposed by Chau and colleagues 82 as "known valid", based on independent confi rmation in several studies.
PET scanning is an emerging technology used to assess the lung in patients with tuberculosis. [83] [84] [85] Positrons emitted by ¹⁸F-fl uorodeoxyglucose quickly collide with electrons, yielding two high-energy photons travelling in For more about the HostDirected Therapies Tuberculosis Consortium Network see http:// www.unza-uclms.org/hdt-net Review opposite directions. Detection of these simultaneous events permits accurate three-dimensional localisation of nuclear events. The combination of PET with CT radiograph imaging gives combined information about infl ammation and structure. PET with CT combination could be an important non-invasive method to assess disease activity, response to therapy, and risk of relapse. The potential role of PET with CT in the early rapid assessment of new tuberculosis drugs is being evaluated in the NexGen EBA trial (NCT02371681).
Whole-blood bactericidal activity against intracellular M tuberculosis is a candidate biomarker for assessment of protective antimycobacterial immunity and chemotherapy. 86, 87 Use of this method during tuberculosis treatment is better in the intensive than the continuation phase, is better for standard versus MDR regimens, and correlates with 2-month culture status. 88 Measurement of whole-blood bactericidal activity has accelerated the development of sutezolid and bedaquiline. 19, 24, 89 Wholeblood bactericidal activity is uniquely suited to assess the combined eff ects of host-directed chemotherapy and antimicrobial chemotherapy. It is being assessed in the TB-host-directed therapies (not yet registered), TB-SEQUEL (not yet registered), and faropenem (NCT02393586) trials.
Gene expression profi les are technical advances in high-throughput techniques that now help with the investi gation of genetic, epigenetic, and proteomic signatures of tuberculosis. 90 A study 91 prospectively assessed 6363 South African adolescents with latent tuber culosis infection to identify gene signatures predicting progression to active tuberculosis. Two signatures, comprising splice junctions from 16 to 21 signal genes and ten reference genes, showed about 66% sensitivity and 81% specifi city for active tuberculosis in the next 12 months. 91 These fi ndings 91 were validated in two independent cohorts that included adults. The signatures, which include interferon module genes and other markers of lung infl ammation, seem to suggest the response to therapy and predict risk of relapse. This signature is being assessed in the TB-HDT trial (table 2) .
Shortening of treatment in drug-susceptible tuberculosis
Relapse (the epigenetic persistence and subsequent reactivation of drug-susceptible but phenotypically tolerant, non-replicating bacilli) is the most common adverse clinical outcome in patients with drug-sensitive tuberculosis. The risk of relapse increases as the duration of treatment is reduced. 80 Identifi cation of shorter regimens that do not unacceptably increase the relapse risk has been a major research focus.
Eff orts to shorten treatment have so far been diverse. Some trials have attempted to identify patient characteristics compatible with shorter treatment. One trial 93 reported 4 months of standard treatment (2 months of daily isoniazid, rifampicin, ethambutol, and pyra zinamide followed by 2 months of daily isoniazid and rifampicin) yielded an acceptable relapse rate of 7% when restricted to patients without cavitary disease at diagnosis and who had negative sputum cultures at 8 weeks. However, this fi nding 93 will not be applicable for most patients with tuberculosis in whom cavitation is present at diagnosis. As a result, most trials have tested new regimens, including new compounds and approved drugs.
Moxifl oxacin and gatifl oxacin have been the subject of several phase 2 and 3 treatment-shortening trials. Phase 2 studies of these drugs in drug-sensitive tuberculosis generally showed small incremental benefi ts on month-2 sputum culture conversion. [94] [95] [96] [97] [98] However, three large, multicentre phase 3 trials (REMox, 7 OFLOTUB, 8 and RIFAQUIN 9 ) reported this benefi t to be insuffi cient to support shortening treatment from 6 months to 4 months, because relapse risks increased from less than 5% in the 6-month groups to more than (table 1) . The transition from phase 2 to phase 3 tuberculosis trials requires the use of biomarker endpoints to predict clinical endpoints. With no success from the three phase 3 fl uoroquinolone trials, [7] [8] [9] shorten ing of tuberculosis treatment has stimulated interest in the application of pharmacometrics and mathematical modelling as applied to tuberculosis biomarkers to guide the progression of studies of new regimens. 79, 80 High doses of rifampicin and rifapentine have also been studied for their use to shorten tuberculosis treatment. In the PanACEA MAMS-TB-01 trial, 3 rifampicin 35 mg/kg per day added to standard doses of isoniazid, pyrazinamide, and ethambutol yielded an improved hazard ratio for stable culture conversion in liquid medium over 12 weeks (hazard ratio 1·75, 95% CI 1·21-2·55) compared with standard doses (table 1) . However, the eff ect on culture status at 8 weeks using solid medium (10% positive vs 15% in controls) is predicted to yield a relapse rate of 13% if administered for only 4 months. 79, 81 In studies of rifapentine the 1200 mg once a day dose proposed for a phase 3 trial Pretomanid (formerly known as PA-824), is a nitroimidazole active against both replicating and nonreplicating M tuberculosis. In aerobic cultures, pretomanid inhibits ketomycolate and cell wall synthesis, 99 whereas in hypoxic cultures nitroimidazole-derived nitrous oxide poisons the respiratory chain and depletes ATP. 100 The NC-002 phase 2b trial 5 examined the effi cacy of regimens consisting of pretomanid 100 mg or 200 mg once a day, plus moxifl oxacin and pyrazinamide. In patients with drug-sensitive tuberculosis, this study 5 reported culture positive using solid medium after 8 weeks in 17% of patients receiving the 100 mg per day and 5·7% in those receiving 200 mg per day groups, compared with 12·5% of patients receiving standard therapy (table 1) . If administered for only 4 months, these drugs are predicted to yield 16% (in those given 100 mg) and 10% (in those given 200 mg) relapses. The trial 5 also enrolled a small number of patients with MDR tuberculosis treated at the 200 mg dose. Three (37·5%) of eight patients remained culture positive at week 8, a result predicted to yield 10% relapses if administered for 6 months. Nonetheless, on the basis of this study 5 a phase 3 trial (NCT02342886; STAND) began in 16 countries in February, 2015, under the sponsorship of the TB Alliance (table 2). The phase 3 study has fi ve treatment groups, of which four groups will be tested in 350 patients (per group) with susceptible tuberculosis (two groups with pretomanid plus moxifl oxacin and pyrazinamide [at 100 mg and 200 mg pretomanid once a day] for 4 months, one at 200 mg a day for 6 months, and one standard therapy group). The fi fth group will be of 350 patients with drug-resistant tuberculosis (to be given 6 months of pretomanid plus moxifl oxacin and pyrazinamide [at 200 mg a day]). Enrolment in the trial was suspended in October, 2015, due to serious hepatic safety concerns. In January, 2016, the concerns have not been resolved and the study remains on clinical hold.
The TB Alliance NC-003 trial (NCT01691534) examined the EBA of various combinations of clofazimine, bedaquiline, pretomanid, and pyrazinamide over 14 days in patients with drug-susceptible tuberculosis. The study found that the combination bedaquiline plus pretomanid and pyrazinamide was safe and highly active in sputum after 14 days. This study was followed by a phase 2b trial, TB Alliance NC-005 (NCT02193776) which started in October, 2014 (trial is ongoing; table 2). The study is assessing regimens that include two diff erent doses of bedaquiline plus pretomanid, and pyrazinamide in drugsensitive tuberculosis, and these drugs in combination with moxifl oxacin in MDR tuberculosis. Its main endpoint is the decrease in counts of colony-forming units in 8 weeks. No results are available.
Improvement of outcomes in patients with MDR tuberculosis
By contrast with drug-susceptible tuberculosis, poor outcomes in MDR tuberculosis more often are representative of treatment failure rather than relapse. 101 Treatment failure precludes patient relapse. 102 Relapses are less common in MDR tuberculosis than drugsensitive tuberculosis, even after accounting for this competing endpoint. 103 However, relapse will likely become more important in MDR tuberculosis trials as more eff ective regimens are studied and shorter treatment durations are judged.
Delamanid (a nitroimidazole) and bedaquiline (a diarylquinoline inhibitor of ATP synthesis) received accelerated approvals based on small trials showing accelerated sputum culture conversion. Both drugs were compared against placebo when added to a standardised background regimen. For delamanid, doses of 100 mg and 200 mg twice a day decreased rates of positive cultures at month 2 from 67% (placebo) to 45% (100 mg) and 37% (200 mg) on solid culture media. 104 Data from subsequent non-randomised rollover studies 105 suggest patients treated with delamanid for 6 months or more had reduced mortality compared with placebo (1% vs 8%, p<0·001). Bedaquiline showed similar eff ects to delamanid on culture conversion, reducing the proportion of positive in liquid culture media from 91% to 52%. 106 However, in long-term follow-up, mortality increased in those patients who had previously received bedaquiline (ten of 79 patients) compared with those in the placebo group (two of 81 patients). 106 The long interval between drug exposure and death (nearly 1 year) hindered assessment of causality, even when the long terminal half-life of bedaquiline was considered. The possible mortality imbalance did not preclude accelerated approval, which illustrated the few options and poor outcomes for patients with MDR tuberculosis generally. 107 A 2015 uncontrolled report 10 of bedaquiline in patients with MDR and XDR tuberculosis noted 16 (6·9%) of 233 deaths during follow-up to week 120. 10 For both bedaquiline and delamanid accelerated approval did not remove the requirement to complete conventional phase 3 trials. WHO has issued interim guidance on the use of bedaquiline 108 in 2013 and delamanid 109 in 2014. By January, 2014, 43 countries reported using bedaquiline as part of treatment regimens to treat specifi c patients with severe forms MDR tuberculosis. 110 Uptake of bedaquiline and delamanid have been slowed, however, by scarcity of knowledge as to their optimum use, prompting further studies assessing these drugs as components of new MDR tuberculosis regimens.
A series of MDR tuberculosis regimens studied sequentially in Bangladesh culminated in the report in 2010 that 9 months of treatment with gatifl oxacin, clofazimine, ethambutol, and pyrazinamide sup plemented by prothionamide, kanamycin, and high-dose isoniazid during an intensive phase of at least 4 months, yielded relapse-free treatment success in 181 (87·9%) of 206 patients. 33, 34 Two observational studies have since reported high long-term eff ectiveness of similar 12-month regimens in Cameroon 11 and Niger 12 in patients with MDR tuberculosis who had not previously received second-line drugs (table 1) . Most recently, fi ndings from a preliminary report 13 of a 9-month Bangladesh-type regimen (in which moxi fl oxacin replaced gatifl oxacin) noted that 75% of patients had converted to culture negative by month 2, and 82% seemed to be cured at end-of-treatment. The 25% month-2 culture positive rate is likely suffi cient to support a 9-month regimen, yielding a predicted relapse rate of 3%. All three studies [11] [12] [13] very likely benefi ted from the low prevalence of pre-XDR, XDR, and HIV in their study populations. The Bangladesh regimen is being studied in the STREAM trial (NCT02409290), 111 with the addition of bedaquiline in some study groups (table 2) . A phase 2b/3 randomised controlled trial of clofazimine in MDR tuberculosis is presently being planned by Novartis (Basel , Switzerland;  table 2 ).
An ongoing phase 3 clinical trial (NCT01424670) is assessing delamanid plus an optimised background regimen in MDR tuberculosis, in which delamanid is given for the fi rst 6 months. A 10-day, open-label pharmacokinetic trial (NCT01856634) of delamanid plus optimised background regimen in children with MDR tuberculosis is ongoing. Patients who successfully complete this trial will then be enrolled in a second, open-label study (NCT01859923) to assess the safety, tolerability, pharma cokinetics, and effi cacy of delamanid plus optimised background regimen for 6 months. Delamanid and bedaquiline will also both be studied, given separately and in combination, in MDR tuberculosis (ACTG study A5343, NCT02583048) to examine eff ects on the cardiac conduction QT interval. Several studies are assessing the possible role of linezolid in phase 3 trials (table 2). The NEXT trial (NCT02454205) is comparing linezolid, bedaquiline, levofl oxacin, pyrazinamide, plus ethionamide with standard therapy. NiX-TB (NCT02333799) is a phase 2b, open-label, adaptive design trial that began enrolling patients with XDR tuberculosis at three South African sites in 2015. The study will investigate the safety and effi cacy of 6-month regimens that include bedaquiline, pretomanid, and linezolid. The primary endpoint is a composite endpoint of bacteriological or clinical failure and relapse, with follow-up for 24 months after the end of treatment. The phase 3 endTB trial 92 (not yet registered) will be undertaken by Partners in Health and Médecins Sans Frontierès in Georgia, Kazakhstan, Kyrgyzstan, Lesotho, and Peru, with support from UNITAID. It will assess fi ve short oral regimens for MDR tuberculosis, each containing combinations of delamanid or bedaquiline, moxifl oxacin or levofl oxacin, linezolid and clofazimine, plus pyrazinamide. 92 Lastly, TB-PRACTECAL (NCT02589782) is a randomised, controlled, open-label, phase 2/3, adaptive-design trial that is assessing the safety and effi cacy of 6-month regimens that contain bedaquiline, pretomanid, and linezolid with or without moxifl oxacin or clofazimine, in patients with MDR or XDR tuberculosis. It will be undertaken in Uzbekistan and Swaziland by Médecins Sans Frontières.
Innovative strategies for new drugs, regimens, and research capacity in MDR tuberculosis
These previously stated observations illustrate the challenges faced by tuberculosis drug developers. In drugsensitive tuber culosis, researchers must contend with a 6-month regimen that is relatively well tolerated and effi cacious in trial conditions, even though it has been diffi cult to implement in real-world settings and yet more diffi cult to improve. In MDR tuberculosis, researchers must contend with control regimens requiring up to 3 years of treatment and follow-up, consisting of drugs that precede the modern regulatory era, to be tested in a patient population that can be diffi cult to recruit.
Four factors now create an unprecedented opportunity for the rapid assessment and licensing of improved new MDR tuberculosis regimens in short innovative trials. Three have been previously discussed in this Review: the availability of new antimycobacterial drugs with novel mechanisms of action and improved safety and tolerability; the increasing recognition of the potential role of host-directed therapies; and the validation of sputum-culture conversion as a predictive biomarker for treatment failure and patient relapse. The last, but perhaps most crucial factor is that of regulatory innovation, the creation of the special medical use and adaptive licensing pathways for registration of new treatments for drug-resistant infections based on small clinical trials. These could potentially replace the requirement for conventional phase 3 trials with enhanced post-licensing outcome reporting. The coalescence of these four factors for MDR tuberculosis, and for tuberculosis generally, could be transformative.
Regulatory agencies balance potential risk against benefi t as they assess new therapies. An imbalance of these factors 25 years ago in antiretroviral drug development resulted in accelerated approvals (subpart H 21CFR314) by the FDA, and conditional market authorisations (EC507/2006) by the European Medical Agency (EMA). These mechanisms substituted a biomarker (plasma HIV RNA) for a clinical endpoint (survival), thus relieving an ethically unacceptable bottleneck in drug develop ment. We now face a similar crisis for drug-resistant bacterial infections, 112 and as a result are at the threshold of further regulatory innovation. New antibacterials are currently tested in large studies of patients who have been readily treated with other drugs, hoping that a small number with highly-resistant infections will enter the new treatment group. The US Presidential Executive Order Combating Antibiotic-Resistant Bacteria 113 and PCAST report Review created a new trials framework (small studies in patients with highly-resistant infections) and a new approval mechanism (eg, special medical use; restricted to specifi c types of patients with few therapeutic alternatives). The approach is consistent with the 21st century Cures Act 115 and the emerging adaptive licensing concept at EMA. 116 A clinical strategy to advance tuberculosis research through trials in MDR tuberculosis incorporating these four innovative elements is shown in fi gure 4. It describes the evaluation as one, and in combination, of three hypothetical candidates. Chances for real-world success might be enhanced by careful selection of these candidates based on preliminary evidence for effi cacy, safety, and pharmacokinetic compatibility. Of the drugs we have discussed, sutezolid, rifabutin, imatinib, metformin, doxycycline, and CC-11050 would meet these criteria. These drugs should be prioritised for assessment in future innovative trials.
MDR tuberculosis was unlikely to have the main consideration of legislators when the special medical use pathway (or its equivalent) were fi rst proposed. However, one cannot imagine a better exemplar to test feasibility and its eff ect. Treatment of MDR tuberculosis off ers rapid diagnostics, validated biomarkers, specially trained physicians, dedicated treatment facilities, globally accepted reporting mechanisms, and the normative roles of several international organisations. Opportunities might arise to coordinate such an eff ort with planned revisions of the MDR tuberculosis recommended drug categories by WHO. Implementation of this concept could remove the requirement to complete large phase 3 trials in hard-to-recruit patient populations, substituting enhanced post-licensing reporting of clinical and safety outcomes. 117 Large risks are deemed acceptable in MDR tuberculosis versus drug-sensitive tuberculosis, due to the greater unmet need and greater potential for patient benefi t. Advances in turn can have great eff ect on patient care, health policy, and capacity strengthening for tuberculosis and infectious diseases generally. Global initiatives-eg, the second programme of the European and Developing Countries Clinical Trials Partnership, 118 the German Ministry for Science and Education, and the US National Institutes of Health-now provide unique opportunities to tackle the tuberculosis epidemic through development of partnerships between high-income countries and middle-income and low-income countries for clinical trials research and training, thus permitting funders to better coordinate national and regional research programmes.
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Search strategy and selection criteria
We restricted our searches to reports published after Jan 1, 1996, in English. We did several searches of PubMed using the search term "tuberculosis" plus "clinical trials", "biomarkers", and "drug development", and individual searches for each of the drugs Q203, SQ109, TBA-354, bedaquiline, delamanid, levofl oxacin, moxifl oxacin, pretomanid, pyrazinamide, rifapentine, rifampicin, and sutezolid (PNU-100480), and compounds identifi ed by the Stop TB Partnership Working Group for New TB Drugs website. We searched the ClinicalTrials.gov website using the term "tuberculosis" alone, and in combination with each of the drugs identifi ed by previous searches (including drugs Q203, SQ109, TBA-354, bedaquiline, delamanid, levofl oxacin, moxifl oxacin, pretomanid, pyrazinamide, rifapentine, rifampicin, and sutezolid [PNU-100480]). We contacted Novartis for information regarding their trial of clofazimine. Finally, we searched the UNITAID website using the term "tuberculosis".
For more on the Stop TB Partnership Working Group for New TB Drugs see http://www.newtbdrugs.org/
